A national study found that use of MRI before prostate biopsy increased in US hospitals from 2017 through the first half of 2026.
|Videos|May 16, 2022
Dr. Rafael Sanchez-Salas on the ideal patient for focal therapy for prostate cancer
Author(s)Urology Times staff
“Focal therapy represents a middle ground between active surveillance and more radical options,” says Rafael Sanchez-Salas, MD.
Advertisement
In this interview, Rafael Sanchez-Salas, MD, also discusses potential complications of focal therapy. Sanchez-Salas is an associate professor of urology in the department of surgery at McGill University in Montreal, Quebec.
Advertisement
Related to this article
The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
A decision is expected by the fourth quarter of 2026.
Marian Cuello joins to discuss sexual wellness and the importance of normalizing conversations about sexual health for all individuals.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Advertisement
Advertisement
Trending on Urology Times
1
Evidence for Combining Prostatic Urethral Lift With Radiotherapy
2
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
3
FDA grants breakthrough device designation to urine ID/AST panel
4
CHMP recommends perioperative enfortumab vedotin plus pembrolizumab for MIBC
5